Beyond basic research: recent clinical research breakthroughs in GIP and GLP1

With the improvement of people's quality of life and the modern sub-healthy lifestyle, the proportion of diseases including diabetes, obesity, hypertension, hyperlipidemia, and coronary heart disease caused by them has significantly increased in the population. GIP and GLP-1 and are both important targets for the treatment of TIID and obesity and have attracted increasing attention in both basic and clinical research. This article mainly discusses the mechanisms of GLP-1 and GIP, two intestinal hormones, in TIID, obesity, and the immune system, as well as their roles in metabolism. It also provides an overview of the clinical effects of related drugs, such as semaglutide and dual receptor agonists. This article has guiding significance for future basic research and clinical medication and underscores the importance of comprehensive research in GLP pharmacology to optimize GLP-targeted drug development and clinical outcomes.